Neuroscientist focused on neurodegenerative diseases, particularly Alzheimer’s disease. Currently leading CNS research at Illimis Therapeutics, developing therapeutic strategies targeting amyloid-beta, tau, and neuroinflammatory pathways, including TAM receptor biology. Experienced in in vivo pharmacology, human brain-based assays, and translational research.